Fri.Dec 06, 2019

AECOM Lands Two Large European Contracts

L.A. Business Journal

Century City-based engineering and infrastructure firm AECOM is taking on two new European construction projects, including what will be the longest rail tunnel in the world

Rocket Lab Puts Seven More Satellites Into Space

socalTECH

Huntington Beach-based Rocket Lab successfully put seven more satellites into space early Friday morning from its launch site in New Zealand, in the company's tenth launch. Rocket Lab launched another of its Electron rockets into space at 6:18am PST, in a mission it called "Running Out of Fingers".

SpaceX 100

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VC Draper Moves into LA

L.A. Business Journal

Timothy Draper has a history of funding some of the technology sector’s most prolific startups and now the venture capitalist is bringing his money to Los Angeles

Draper 130

SpaceX Successfully Launches Another Payload To ISS

socalTECH

Hawthorne-based SpaceX successfully launched yet another payload to the International Space Station (ISS) on Thursday, launching a SpaceX Falcon 9 rocket to space from Cape Canaveral Air Force Station and launchpad SLC-40. The SpaceX Dragon is delivering science investigations, supplies and equipment. The SpaceX CRS-19 mission is delivering 5,700 pounds of supplies and payloads to the ISS.

SpaceX 100

LAVA Holiday Party and Global LAVA Relaunch

SoCal Tech Calendar

Thursday, December 12, 2019 -- LAVA Holiday Party and Global LAVA Relaunch. LAVA Holiday Party and Global LAVA Relaunch! Join us for a celebration of the season and the success of 2019! A special Holiday Party and relaunch of Global LAVA. Special Venue is Delair Studios in Hollywood. Come visit with LAVA members and Friends. Also featured is the Delair Studio Screening Room and a special screening using a new cinematic projection and audio system. See [link] (more

LAVA 100

Wave Neuroscience Acquires Newport Brain Research Laboratory

socalTECH

Newport Beach-based Wave Neuroscience , a newly formed startup, says it has acquired a number of assets from Newport Brain Research Laboratory (NBRL), along with "many different onshore and offshore holding companies" owned by NBRL, as part of its efforts to provide non-invasive neuromodulation technology. The company said it is focused on brain health, and treating Traumatic Brain Injuries (TBI) and Post-Traumatic Stress Disorder (PTSD).

More Trending

Qualcomm Ties With Niantic, Maker of Pokemon Go, For AR Efforts

socalTECH

San Diego-based Qualcomm has launched a new chip for the augmented reality / virtual reality market, saying this week at the Snapdragon Tech Summit that it has also linked with Pokemon Go creator Niantic , as part of an effort to in the augmented reality market.

3 Takeaways From the Resurrection of Biogen’s Alzheimer’s Drug

Xconomy

The name of the experimental drug was heard so frequently in hotel hallways at the conference that it sounded like an incantation: aducanumab, aducanumab, aducanumab.

Interview with Jon Grishpul, GreatBuildz

socalTECH

How do you find a good contractor for your home remodeling project? Encino-based GreatBuildz (www.greatbuildz.com) says it's a high touch, concierge service. For our interview today, we talked with CEO and co-founder Jon Grishpul about the startup, which offers up its services for free to homeowners in the Los Angeles area. What is GreatBuildz? Jon Grishpul: GreatBuildz is a free service, where we help homeowners find reliable, vetted general contractors, and provide support during the project.

Encino 100

Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis

Xconomy

Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients. The Acadia (NASDAQ: ACAD ) drug pimavanserin (Nuplazid) is currently approved for treating psychosis associated with Parkinson’s disease.

Study 52

Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More

Xconomy

It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause. Clearing proteins, such as amyloid and tau, was once seen as the top contender for stopping or slowing neurodegeneration. Costly failures forced researchers to look at other targets.